<DOC>
	<DOCNO>NCT02170519</DOCNO>
	<brief_summary>Acute secondary pulmonary hypertension ( PH ) often lead dysfunction right ventricle ( RV ) significant cause patient morbidity mortality . Selective pulmonary vasodilation inhale nitric oxide ( INO ) become treatment choice condition . The evidence support INO safety efficacy circumstance sparse , however , largely extrapolate use INO neonatal pulmonary hypertension . Moreover , high cost potential toxicity INO make therapy far ideal . Emerging evidence suggest inhale aerosolized prostacyclins iloprost may favorable alternative therapy .</brief_summary>
	<brief_title>Inhaled Aerosolized Prostacyclin Pulmonary Hypertension Requiring Inhaled Nitric Oxide</brief_title>
	<detailed_description>Phase 1- In original study , 3 dos Iloprost give . This revise 5 subject enrol order study effect continuous delivery longer period time . Phase 2 - All remain subject receive Iloprost continuous treatment . The study design enrollment 200 subject end early .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Iloprost</mesh_term>
	<mesh_term>Epoprostenol</mesh_term>
	<mesh_term>Tezosentan</mesh_term>
	<mesh_term>Nitric Oxide</mesh_term>
	<criteria>1 . Clinical evidence pulmonary hypertension ( PH ) require INO therapy prescribe attend physician . 2 . Indwelling arterial catheter . 3 . Signed informed consent 1 . Clinically unstable circulatory condition require epinephrine &gt; 0.1 mcg/kg/min levophed , already meet treatment failure criterion ( see section 5.3 ) 2 . Known hypersensitivity prostacyclin compound 3 . Patients receive sildenafil bosentan 4 . Refusal attend physician</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>pulmonary hypertension</keyword>
</DOC>